

Towards the elimination of hepatitis B and hepatocellular carcinoma

C W Spearman, MB ChB, FCP(SA), MMed, PhD

Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa

Corresponding author: C W Spearman

Hepatitis B (HBV) remains a global health problem despite the availability of effective vaccines since 1982 and effective antiviral therapy. The global burden of disease is substantial, with HBV resulting in 887 220 deaths in 2015: acute hepatitis (87 076), cirrhosis (462 690) and hepatocellular carcinoma (337 454). The World Health Organization has a vision to eliminate viral hepatitis as a public health threat by 2030. Although HBV and its associated complications of cirrhosis, liver failure and hepatocellular carcinoma are entirely vaccine preventable, there is no cure for chronic hepatitis B as yet. HBV elimination strategies will need to focus on effective and implementable preventive and therapeutic strategies such as upscaling HBV birth-dose vaccination, full HBV vaccine coverage, vaccination of high-risk groups, prevention of mother-to-child transmission, and identification of HBV-infected individuals and linkage to care with sustainable access to antiviral therapy.

S Afr Med J 2018;108(8 Suppl 1):S13-S16. DOI:10.7196/SAMJ.2018.v108i8.13496

Hepatitis B (HBV) remains a global health problem despite the availability of effective vaccines since 1982 and effective antiviral therapy. Two billion people have serologic evidence of past or ongoing HBV infection and an estimated 257 million people or 3.5% of the world's population, are chronically infected with HBV.^[1] The lifetime risk of cirrhosis, liver failure and hepatocellular carcinoma (HCC) is 15 - 40%. Globally, hepatitis B mortality is increasing, while HIV/AIDS mortality is decreasing with the advent of antiretroviral therapy (ART).^[2] Globally in 2015, HBV caused 887 220 deaths: acute hepatitis ($n=87\ 076$), cirrhosis ($n=462\ 690$) and HCC ($n=337\ 454$); in Africa, HBV was responsible for 87 890 deaths.^[1]

In May 2016, the World Health Organization (WHO) adopted a global hepatitis strategy with the goal of eliminating viral hepatitis as a public health threat by 2030. The targets to be achieved by 2030 are ambitious: 90% reduction in new cases of chronic hepatitis B and C; 65% reduction in mortality due to hepatitis B and C; and 80% of treatment-eligible persons with chronic hepatitis B and C infections being treated.^[3]

Hepatitis B epidemiology

HBsAg seroprevalence varies geographically. According to the recent 2017 WHO Global Hepatitis Report, the number of HBsAg-positive individuals was highest in the Western Pacific (115 million, prevalence estimate 6.2%; 95% uncertainty interval 5.1 - 7.6%) and Africa (60 million, prevalence estimate 6.1%; 95% uncertainty interval 4.6 - 8.5%) regions, which together accounted for 68% of the global burden.^[1] The annual incidence of hepatocellular carcinoma correlates with the hepatitis B surface antigen (HBsAg) seroprevalence; the highest incidence is found in sub-Saharan Africa (SSA) and South East Asia.

In the absence of effective mother-to-child-transmission (MTCT) prophylaxis, HBV endemicity and chronicity is established in early childhood, with HBsAg seroprevalence studies showing no difference between children aged 5 - 9 years and adults.^[4] The risk of chronicity of HBV is determined by the age of acquisition of infection: 90% after neonatal infection (in children born to HBeAg-positive or highly

viraemic mothers), 20 - 50% with childhood infection (<5 years of age) and <5% for adults >20 years.

HIV/HBV co-infection has a further impact as HIV promotes a more aggressive natural history of hepatitis B. HIV co-infection promotes increased HBV replication and rates of HBV reactivation; increased hepatitis B e-antigen (HBeAg) seroconversion; increased rates of occult HBV; chronicity of newly acquired HBV infections with a five times faster progression to fibrosis and cirrhosis; HCC also occurs at a younger age and is more aggressive.^[5-16]

Achieving elimination of hepatitis B

In order to achieve the WHO's ambitious 2030 targets of elimination, it will be essential to recognise the burden of disease within one's own country, i.e. know the seroprevalence and potential high-risk groups; implement HBV vaccine programmes for high-risk groups; address the risk of MTCT; identify HBV-infected individuals and ensure linkage to care; recognise and address potential stigma associated with hepatitis B; and have implementable preventive, surveillance and treatment strategies. It is imperative to recognise and address potential challenges associated with achieving the elimination of HBV while recognising that hepatitis B and its associated complications are entirely vaccine preventable.

Universal HBV vaccination

Vaccination remains the cornerstone of any elimination strategy. The WHO recommended incorporation of HBV vaccination into the Expanded Program of Immunization (EPI) in 1991 as the most effective way to reduce the global burden of HBV. WHO's 2030 target is 90% full HBV vaccine coverage and in 2015, the global HBV 3 dose vaccine coverage was 84%, but only 77% in the WHO Africa region. In contrast, the Western Pacific region has achieved 90% coverage.^[1,17]

Universal vaccination has globally decreased HBsAg prevalence in children under 5 years of age from 4.7% in pre-vaccination era to 1.3% in 2015, but the prevalence in the WHO Africa region remains high at 3%.^[1] The Western Pacific region has reduced their HBsAg prevalence in under-5-year-olds to 0.9%. By 2013, universal HBV vaccination had prevented 14.2 million cases of chronic HBV

infection among children aged 0 - 5 years worldwide and more than 1.3 million deaths.^[18]

Mother-to-child transmission of hepatitis B

HBV MTCT prevention strategies include antenatal HBsAg screening, hepatitis B birth-dose (HepB-BD) vaccination, administration of hepatitis B immunoglobulin to the newborn, and third-trimester antiviral therapy for women with high infectivity risk (HBeAg-positive and/or HBV DNA >200 000 IU/mL) and full HBV vaccine coverage.^[19-21] Modelling studies have suggested that an 80% global scale-up of HepB-BD vaccination plus infant vaccination, compared with scaling-up of infant vaccination alone, could avert 18.7 million new chronic infections over the next 15 years, confirming its importance as a PMTCT tool.^[22]

In 2009, WHO recommended HepB-BD vaccination, with a monovalent HBV vaccine administered within 24 hours of delivery for all countries.^[23] However, globally in 2014, only 96 of 194 countries (49%) reported offering HepB-BD as part of their national immunisation programmes and <38% of babies born worldwide received HepB-BD within 24 hours after birth.^[1,17] Of concern, only 11 of 47 WHO Africa region countries (23%) had introduced HepB-BD vaccine by July 2017, and this is far below the WHO 2030 vaccination target of 90% birth-dose vaccination coverage.^[24] HepB-BD vaccine given within 24 hours after birth and followed by at least two subsequent doses, is ~90% effective at preventing perinatal HBV infection. Innovative approaches to ensure timely administration of Hep B-BD vaccine that have been successfully employed in Vietnam, Indonesia and China, i.e pregnancy tracking and administration of the Hep B-BD by village lay workers as well as the use of compact pre-filled auto-disposable devices (Uniject; Becton, Dickinson and Company, USA) are translatable to SSA.^[25-27]

While the risk of MTCT of HIV is well recognised and policies are in place to screen all pregnant women for HIV and initiate ART, many countries in SSA do not have similar policies in place for HBV despite WHO recommending antenatal HBsAg screening in countries where HBsAg prevalence is $\geq 2\%$.^[1,28,29] This is concerning as the annual number of infants perinatally infected with HBV is twice the number of incident paediatric HIV infections in SSA.^[30] Standard-of-care procedures need to be in place to communicate the HBsAg status to the delivery unit to assess the need for third-trimester tenofovir prophylaxis for HBeAg-positive or highly viraemic (HBV DNA >200 000 IU/ml) pregnant women and to emphasise the importance of timely HBV birth-dose vaccination within 24 hours of delivery.^[28] Timely administration is important as there is an increased risk of HBV transmission if HB-BD is given 7 days after delivery compared to 1 - 3 days post delivery (OR 8.6).^[28] Immunisation programmes also need to ensure a timely second dose of HBV vaccination to infants born to mothers with chronic HBV infection as the risk of becoming chronically infected was 3.74 times (95% confidence interval (CI) 0.97 - 14.39) higher if the interval between the first and the second doses exceeded 10 weeks.^[31] Identification of HBsAg-positive pregnant women also provides the opportunity to identify potentially HBV-infected partners, siblings and children and thereby link them to care and break ongoing cycles of infection.

Efficacy of universal hepatitis B vaccination: Impact on liver disease

This has proved exemplary in Taiwan, where universal vaccination, introduced in 1984, together with a catch-up vaccination programme and improved maternal screening, resulted in a decrease in the prevalence of HBsAg positivity in children aged <15 years from 9.8%

in 1984 to 0.3% in 2009 and continues to decrease 30 years after initiation of universal vaccination.^[32-34] Furthermore, HCC incidence per 10⁵ person-years has decreased from 0.92 in unvaccinated to 0.23 in vaccinated cohorts.^[35]

In Alaska, universal newborn HBV vaccination, vaccine catch-up programmes and mass screening since 1981 have eliminated acute symptomatic HBV infection and early-onset HCC as a public health threat among Alaskan Native (AN) children. The incidence of acute symptomatic HBV infection in AN persons <20 years of age decreased from 19/100 000 in 1981 - 1982 to no reported cases since 1992. The incidence of HCC in AN persons <20 years decreased from 3/100 000 in 1984 - 1988, with no reported cases since 1998. The number of identified HBsAg-positive AN persons <20 years declined from 657 in 1987 to 2 cases identified since 1999; the last HBsAg-positive AN person <20 years of age was identified in 2010.^[36]

A similar decline in HBsAg seroprevalence rate and in HCC incidence has been seen in other hepatitis B endemic countries which have implemented universal HBV vaccination.^[37-39]

Full HBV vaccine coverage is important, as incomplete immunisation has been shown to be an important risk predictor for HCC (HR 2.52; 95% confidence interval (CI) 1.25 - 5.05; $p=0.0094$) and chronic liver disease (HR 6.27; 95% CI 3.62 - 10.84; $p<0.0001$) after correction for maternal HBsAg status.^[40]

Public-private partnerships play an important role in achieving the elimination of hepatitis B. The success of HepB-BD vaccine and full vaccine coverage in preventing childhood HBV acquisition has been demonstrated in China. A partnership between Gavi, the Vaccine Alliance and the Chinese government supporting free HepB-BD vaccination in combination with up-scaling of the full HBV vaccine schedule and utilising village lay healthcare workers to administer the HepB-BD vaccine, has reduced HBsAg seroprevalence in 2009 to 0.96% in children <5 years of age compared with 9.67% in 1992.^[41]

Durability of universal HBV vaccination

In a 30-year follow-up study, 243 individuals of a cohort of 1 578 AN adults and children who had responded to the original primary series but received no subsequent booster doses were screened for immunity; 125 (51%) individuals had an anti-HBs level ≥ 10 mIU/mL at 30 years. Among participants with anti-HBs levels <10 mIU/mL who were available for follow-up, 88% ($n=75/85$) responded to a booster dose with an anti-HBs level ≥ 10 mIU/mL at 30 days, indicating immunological memory. Thus, ~90% (range 74 - 100%) had evidence of protection 30 years after vaccination.^[42]

A meta-analysis of 22 studies assessed 11 090 persons 5 - 20 years post vaccination and showed no evidence of chronic infection and 0.7% evidence of past exposure (anti-HBc-positive).^[43] Boosters were not needed in immunologically competent individuals following a full primary course of HBV vaccination.^[43,44]

Identification of HBV-infected individuals and linkage to care

In 2015, it was estimated that globally only 9% of HBV-infected individuals (22 million) were aware of their diagnosis and only 8% of diagnosed HBV-infected individuals (1.7 million) had been treated.^[1]

In order to prevent the life-threatening complications of cirrhosis, liver failure and HCC, it is essential to identify HBV-infected individuals to assess the need for treatment and appropriate frequency of follow-up. Accurate WHO pre-qualified HBV point-of-care (POC) testing that can be easily administered at primary levels of healthcare is essential to upscale diagnosis and treatment.

The PROLIFICA project has validated 3 point-of-care rapid diagnostic tests (Determine, Vikia and Espline), both in the field and laboratory settings in the Gambia. All 3 tests had acceptable ranges of diagnostic accuracy and are inexpensive alternatives to laboratory-based testing.^[45] Once diagnosed, HBV-infected individuals need to be linked to care and this will require the establishment of clear pathways of referral. Less than 20% HBV-infected individuals require treatment and the need for treatment and frequency of follow-up is determined by age, ALT, presence of fibrosis, HBeAg status, HBV DNA levels and family history of cirrhosis or HCC.^[46]

The PROLIFICA project also demonstrated that large scale test-and-treat programmes are feasible and cost-effective in endemic countries such as SSA.^[47,48]

Appropriate HBV antiviral therapy has been shown to have an impact on the development of cirrhosis and risk of HCC, improving liver-related and all-cause mortality.^[49-52] Lamivudine, entecavir and tenofovir have all been shown to decrease mortality. Tenofovir, which has a high barrier against resistance, is the WHO preferred antiviral.^[46] Unfortunately, although tenofovir and lamivudine/emtricitabine are widely available as part of ART, these nucleotide analogues are not always accessible to patients with HBV mono-infection in many SSA countries.

Addressing important co-factors in HCC development in chronic HBV infection

There are a number of important co-factors that increase the risk of hepatitis B-related HCC that also need to be addressed.^[53,54] The mycotoxin aflatoxin B1 (AFB1) is potent hepatocarcinogen that contaminates crops, especially maize, groundnuts and sorghum in tropical and subtropical climates such as South-East Asia and sub-Saharan Africa, especially in West Africa. AFB1 contamination occurs during the growth of crops and during improper storage, and individuals are exposed as early as *in utero* as AFB1 crosses the placenta. Subsistence farming, poor crop storage and suboptimal processing increase the risk of AFB1 exposure.^[55] HBV and AFB1 are synergistically hepatocarcinogenic and a systematic review and meta-analysis revealed an overall population attributable risk of AFB1-related HCC of 17% (14 - 19%), with 21% in HBsAg-positive and 8.8% in HBsAg-negative individuals. The relative risk of HCC was 54.1 (95% CI 21.3 - 137.7) with dual exposure.^[56]

Other important HCC co-factors that need to be addressed are alcohol, iron overload and increasingly obesity and associated non-alcoholic fatty liver disease.^[57,58]

Cumulative HCC risk scores for HBV-related HCC have mainly been validated in Asian patients and are weighted for the presence of cirrhosis and increasing age.^[59] These HCC risk-predictor models have not been validated in SSA, where 40% of HCC occurs in young non-cirrhotic patients.

Conclusion

Hepatitis B and its associated complications of cirrhosis, liver failure and HCC are entirely vaccine preventable. In order to achieve the WHO 2030 vision of eliminating HBV, it is imperative that countries implement the WHO recommendations of HBV birth-dose vaccine, full vaccine coverage, and upscale diagnosis and linkage to care of HBV-infected individuals.

The WHO Global Health Sector Strategy on Viral Hepatitis is to reduce new cases of chronic HBV infection by 30% by 2020, which is equivalent to 1% HBsAg prevalence amongst children aged 5 years, aiming for 0.1% HBsAg prevalence in 5-year-olds by 2030.

The full clinical impact of HBV birth-dose vaccination will take 2 - 3 decades and it is essential that HBV-infected individuals are linked to care with appropriate therapy and follow-up, and high-risk non-immune individuals are vaccinated. Although antiviral therapy has reduced both liver-related and all-cause mortality, the risk of HCC in HBV-infected individuals, albeit reduced, is not eliminated and lifelong antiviral therapy and follow-up are usually necessary. Future therapeutic endeavours are aimed at not only a functional cure but also a virological cure with eradication of the intrahepatic HBV reservoir, the covalently closed circular HBV DNA.^[60]

Acknowledgements. None.

Author contributions. Sole author.

Funding. None.

Conflicts of interest. None.

- World Health Organization. Global Hepatitis Report, 2017. Geneva: WHO, 2017. www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (accessed 31 March 2018).
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. *Lancet* 2012;380(9859):2095-128. [https://doi.org/10.1016/S0140-6736\(12\)61728-0](https://doi.org/10.1016/S0140-6736(12)61728-0)
- World Health Organization. WHO Global Health Sector Strategy on Viral Hepatitis 2016 - 2021: Towards Ending Viral Hepatitis. Geneva: WHO, 2016. <https://www.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf> (accessed 31 March 2018).
- Maynard JE. Hepatitis B: Global importance and need for control. *Vaccine* 1990;8(Suppl):S18-S20.
- Kourits AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV co-infection - a global challenge. *N Engl J Med* 2012;366(19):1749-1752. <https://doi.org/10.1056/NEJMp1201796>
- Matthews PC, Geretti AM, Goulder PJ, Klennerman P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. *J Clin Virol* 2014;61(1):20-33. <https://doi.org/10.1016/j.jcv.2014.05.018>
- Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. *Lancet Infect Dis* 2007;7(6):402-409. [https://doi.org/10.1016/S1473-3099\(07\)70135-4](https://doi.org/10.1016/S1473-3099(07)70135-4)
- Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. *J Hepatol* 2006;44(1 Suppl):S65-S70. <https://doi.org/10.1016/j.jhep.2005.11.015>
- Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. *Antivir Ther* 2011;16(3):405-411. <https://doi.org/10.3851/IMP1783>
- Mphahlele MJ. Impact of HIV co-infection on hepatitis B prevention and control: A view from Sub-Saharan Africa. *S Afr J Epidemiol Infect* 2008;23(1):14-18. <https://doi.org/10.1080/10158782.2008.1441294>
- Mayaphi SH, Roussow TM, Masemola DP, et al. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. *S Afr Med J* 2012;102(3):157-162.
- Andersson MI, Maopona TG, Ijaz S, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. *Vaccine* 2013;31(47):5579-5584. <https://doi.org/10.1016/j.vaccine.2013.08.028>
- Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002;360(9349):1921-1926.
- Puoti M, Spinetti A, Ghezzi AJ, et al. Mortality for liver disease in patients with HIV infection: a cohort study. *J Acquir Immune Defic Syndr* 2000;24(3):211-217.
- Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. *Arch Intern Med* 2006;166(15):1632-1641. <https://doi.org/10.1001/archinte.166.15.1632>
- Sonderup MW, Wainwright H, Hall P, Hairwadi H, Spearman CW. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. *Hepatology* 2015;61(5):1721-1729.
- World Health Organization (WHO). WHO/UNICEF Estimates of National Immunization Coverage. Geneva: WHO, 2016.
- Jones E, Edmunds J, Apolloni A, et al. Estimating the impact of HBV vaccination policies. <http://www.who.int/im-munization/sage/meetings/2016/october/Session9-Estimating-the-impact-of-HBV-vaccination-policies.pdf> (accessed 31 March 2018).
- Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces peri-natal transmission of hepatitis B virus in real-life practice. *Hepatology* 2014;60(2):468-476
- Del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijting RA. Failure of neonatal hepatitis B vaccination: The role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. *J Hepatol* 1994;20(4):483-486.
- Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. *N Engl J Med* 2016;374(24):2324-2334. <https://doi.org/10.1056/NEJMoa1508660>
- Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. *Lancet Infect Dis* 2016;16(12):1399-1408. [https://doi.org/10.1016/S1473-3099\(16\)30204-3](https://doi.org/10.1016/S1473-3099(16)30204-3)
- World Health Organization. Hepatitis B Vaccines. *Weekly Epidemiological Record* 2009;84(40):405-420.
- Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B control in the African region. *Pan Afr Med J* 2017;27(Suppl 3):17. <https://doi.org/10.11604/pamj.supp.2017.27.3.11981>
- Cui F, Liang X, Gong X, et al. Preventing hepatitis B through universal vaccination: Reduction of inequalities through the GAVI China project. *Vaccine* 2013;31(Suppl 9):J29-35. <https://doi.org/10.1016/j.vaccine.2012.07.048>
- Murakami H, Van Cuong N, Huynh L, Hippgrave DB. Implementation of and costs associated with providing a birth-dose of hepatitis B vaccine in Viet Nam. *Vaccine* 2008;26:1411-1419. <https://doi.org/10.1016/j.vaccine.2008.01.002>
- Creati M, Saleh A, Ruff TA, Stewart T, Otto B, Sutanto A, Clements CJ. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. *Vaccine* 2007;25(32):5985-5993. <https://doi.org/10.1016/j.vaccine.2007.05.055>
- World Health Organization (WHO). Hepatitis B vaccines: WHO Position Paper - July 2017. *Vaccine Weekly Epidemiol Rec* 2017;92(27):369-392.
- World Health Organization (WHO). Preventing Perinatal Hepatitis B Virus Transmission: A Guide for Introducing and Strengthening Hepatitis B Birth Dose Vaccination. Geneva: WHO, 2015. <https://www.who.int/iris/handle/10665/208278> (accessed 31 March 2018).

30. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. *Aliment Pharmacol Ther* 2016; 44(10):1005-1017. <https://doi.org/10.1111/apt.13795>
31. Tharmaphornpias P, Rasdjarnearnsook AO, Plianpanich S, Sa-nguanmoo P, Poovorawan Y. Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination. *Vaccine* 2009;27:6110-6115. <https://doi.org/10.1016/j.vaccine.2009.08.034>
32. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3 464 infants of hepatitis B surface antigen-carrier mothers. *JAMA* 1988;260(15):2231-2235.
33. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. *JAMA* 1996;276(11):906-908.
34. Ni YH, Chang MH, Jan CE, et al. Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan. *Clin Gastroenterol Hepatol* 2016;14(9):1324-1330. <https://doi.org/10.1016/j.cgh.2016.04.030>
35. Chang MH, You SL, Chen CJ, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. *Gastroenterology* 2016;151(3):472-480. <https://doi.org/10.1053/j.gastro.2016.05.048>
36. Singleton R, Gounder P. Control of acute hepatitis B and hepatocellular carcinoma in Alaska: Follow up 32 years after a hepatitis B Newborn and catchup immunization program. Abstract presented at Second World Indigenous Peoples' Conference on Viral Hepatitis, August 8 - 9, 2017, Alaska Pacific University, Anchorage, Alaska.
37. Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. *Asian Pac J Cancer Prev* 2008;9(3):507-509.
38. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. *Hepatology* 2011;54(3):801-817. <https://doi.org/10.1002/hep.24442>
39. Kim H, Shin AR, Chung HH, et al. Recent trends in hepatitis B virus infection in the general Korean population. *Korean J Intern Med* 2013;28(4):413-419. <https://doi.org/10.3904/kjim.2013.28.4.413>
40. Chien YC, Jan CE, Chiang CJ, Kuo HS, You SL, Chen CJ. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: A 20-year cohort study of 3.8 million vaccinees. *Hepatology* 2014;60(1):125-132. <https://doi.org/10.1002/hep.27048>
41. Cui F, Liang X, Gong X, et al. Preventing hepatitis B through universal vaccination: Reduction of inequalities through the GAVI China project. *Vaccine* 2013;31(Suppl 9):J29-35. <https://doi.org/10.1016/j.vaccine.2012.07.048>
42. Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: Results of a 30-year follow-up study and response to a booster dose. *J Infect Dis* 2016;214(1):16-22. <https://doi.org/10.1093/infdis/jiv748>
43. Poorolajal J, Mahmoodi M, Majdzadeh R, et al. Long-term protection provided by hepatitis B vaccine and need for booster dose: A meta-analysis. *Vaccine* 2010;28(3):623-631. <https://doi.org/10.1016/j.vaccine.2009.10.068>
44. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. *Clin Infect Dis* 2011;53(1):68-75. <https://doi.org/10.1093/cid/cir270>
45. Njai HF, Shimakawa Y, Sanneh B, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. *J Clin Microbiol* 2015;53(4):1156-1163. <https://doi.org/10.1128/JCM.02980-14>
46. World Health Organization. WHO Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: WHO, 2015. www.who.int/mediacentre/news/releases/2015/hepatitis-b-guideline/en/ (accessed 31 March 2018).
47. Lemoine M, Shimakawa Y, Njie R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: The prevention of liver fibrosis and cancer in Africa (PROLIFICA) study. *Lancet Glob Health* 2016;4(8):e559-e567. [https://doi.org/10.1016/S2214-109X\(16\)30130-9](https://doi.org/10.1016/S2214-109X(16)30130-9)
48. Nayagam S, Conteh L, Sicuri E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: An economic modelling analysis. *Lancet Glob Health* 2016;4(8):e568-578. [https://doi.org/10.1016/S2214-109X\(16\)30101-2](https://doi.org/10.1016/S2214-109X(16)30101-2)
49. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology* 2010;52(3):886-893. <https://doi.org/10.1002/hep.23785>
50. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. *Lancet* 2013;381(9865):468-475. [https://doi.org/10.1016/S0140-6736\(12\)61425-1](https://doi.org/10.1016/S0140-6736(12)61425-1)
51. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. *Hepatology* 2013;58(5):1537-1547. <https://doi.org/10.1002/hep.26301>
52. Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. *Liver Int* 2014;34(Suppl 1):139-145. <https://doi.org/10.1111/liv.12394>
53. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. *Best Pract Res Clin Gastroenterol* 2014;28(5):753-770. <https://doi.org/10.1016/j.bpg.2014.08.007>
54. Kew MC. Hepatocellular carcinoma: Epidemiology and risk factors. *J Hepatocell Carcinoma* 2014;1:115-125. <https://doi.org/10.2147/JHC.S44381>
55. Afum C, Cudjoe L, Hills J, et al. Association between aflatoxin M1 and liver disease in HBV/HCV infected persons in Ghana. *Int J Environ Res Pub Health* 2016;13(4):377. <https://doi.org/10.3390/ijerph13040377>
56. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis. *Eur J Cancer* 2012;48(14): 2125-2136. <https://doi.org/10.1016/j.ejca.2012.02.009>
57. Kew MC. Hepatic iron overload and hepatocellular carcinoma. *Liver Cancer* 2014;3(1):31-40. <https://doi.org/10.1159/000343856>
58. Kew MC. Obesity as a cause of hepatocellular carcinoma. *Ann Hepatol* 2015;14(3):299-303.
59. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 2015;62(2):363-370. <https://doi.org/10.1016/j.jhep.2014.08.045>
60. Emery JS, Feld JJ. Treatment of hepatitis B virus with combination therapy now and in the future. *Best Pract Res Clin Gastroenterol* 2017;31(3):347-355. <https://doi.org/10.1016/j.bpg.2017.04.007>